Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02769065 · ClinicalTrials.gov registry record · Phase 1
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 179
- Enrollment target
NCT02769065 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 179 participants.
The verdict
NCT02769065, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 179 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety, tolerability, and pharmacokinetic (PK) of TAK-071 when administered as single rising dose (SRD) and multiple rising dose (MRD) orally in healthy participants and participants with mild cognitive impairment (MCI) or mild Alzheimer disease (AD).
Interventions
- DRUG Donepezil
- DRUG TAK-071
- DRUG TAK-071 Placebo
- DRUG Donepezil Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2016-05-05 |
| Est. Completion | 2017-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02769065
The ClinicalTrials.gov registry entry for NCT02769065 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Donepezil is the first listed.
NCT02769065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02769065 about?
NCT02769065 is a clinical study titled "Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants". The purpose of this study was to assess the safety, tolerability, and pharmacokinetic (PK) of TAK-071 when administered as single rising dose (SRD) and multiple rising dose (MRD) orally in healthy participants and participants with mild cognitive impairment (MCI) or mild Alzheimer disease (AD).
What is the current status of trial NCT02769065?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 179 participants. The study started on 2016-05-05. Estimated completion is 2017-06-08.
What interventions are being tested in trial NCT02769065?
The interventions under investigation include: Donepezil (DRUG), TAK-071 (DRUG), TAK-071 Placebo (DRUG), Donepezil Placebo (DRUG).
Who is sponsoring clinical trial NCT02769065?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.